AnaptysBio (NASDAQ:ANAB) Releases Quarterly Earnings Results, Misses Estimates By $0.82 EPS

AnaptysBio (NASDAQ:ANAB) released its quarterly earnings results on Monday. The biotechnology company reported ($1.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.82), Yahoo Finance reports. AnaptysBio had a negative return on equity of 161.40% and a negative net margin of 711.17%. The business had revenue of $10.97 million during the quarter, compared to analyst estimates of $25.85 million.

AnaptysBio Stock Down 0.9 %

AnaptysBio stock opened at $32.08 on Wednesday. AnaptysBio has a 52-week low of $13.36 and a 52-week high of $38.85. The firm has a market cap of $876.39 million, a PE ratio of -5.22 and a beta of -0.25. The company’s 50 day moving average is $28.03 and its two-hundred day moving average is $25.11.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ANAB. SVB Leerink began coverage on AnaptysBio in a report on Tuesday, April 16th. They set an “outperform” rating and a $47.00 target price for the company. JPMorgan Chase & Co. raised AnaptysBio from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $29.00 to $69.00 in a research note on Friday, July 19th. Wedbush reaffirmed an “outperform” rating and set a $34.00 target price on shares of AnaptysBio in a research note on Friday, May 10th. HC Wainwright reiterated a “buy” rating and issued a $55.00 target price on shares of AnaptysBio in a research report on Tuesday. Finally, Wells Fargo & Company began coverage on shares of AnaptysBio in a research report on Thursday, April 11th. They set an “overweight” rating and a $56.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $51.89.

Insiders Place Their Bets

In related news, insider Paul F. Lizzul sold 1,500 shares of AnaptysBio stock in a transaction on Thursday, July 18th. The stock was sold at an average price of $35.00, for a total value of $52,500.00. Following the completion of the transaction, the insider now directly owns 11,618 shares in the company, valued at $406,630. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, Director Hollings Renton sold 1,950 shares of the business’s stock in a transaction that occurred on Tuesday, June 18th. The stock was sold at an average price of $23.16, for a total transaction of $45,162.00. Following the completion of the sale, the director now owns 1,950 shares in the company, valued at $45,162. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Paul F. Lizzul sold 1,500 shares of the business’s stock in a transaction that occurred on Thursday, July 18th. The stock was sold at an average price of $35.00, for a total transaction of $52,500.00. Following the sale, the insider now owns 11,618 shares of the company’s stock, valued at approximately $406,630. The disclosure for this sale can be found here. Insiders sold a total of 16,900 shares of company stock worth $484,824 over the last 90 days. Corporate insiders own 33.70% of the company’s stock.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.